Diabetes · Diabetes mellitus
王*军· 45 male
- Country
- China
- Diagnosis date
- 2024-03
- Treatment start
- 2024-06
Anamnesis
Wáng*Jūn, male, age 45. In March 2024, routine health check revealed fasting blood glucose 6.23 mmol/L, HbA1c 6.1% — no treatment initiated. BMI elevated. May 2024 follow-up showed fasting glucose 7.58 mmol/L, HbA1c 7.0%.
Treatment plan
June 2024: perinatal NK 2U IV + mesenchymal stem cells 9U IV, once monthly, 2 consecutive administrations.
- Therapy
- NK perinatalUC-MSC (umbilical cord MSC)
- Delivery route
- Intravenous (IV)
Outcome
After one course of mesenchymal stem cell therapy with regular follow-up, the patient is no longer taking oral hypoglycemics. Fasting glucose now within normal range, HbA1c around 5.6%. Stable glycemic control achieved, further progression prevented.
Physician conclusion
No adverse reactions observed. Stem cell infusion increases islet β-cell count, effectively regulates glucose and insulin levels, improves islet function, and controls insulin resistance.
Related cases
- Diabetes mellitus李* · 60
By day 3 post-infusion, blood glucose stabilized. On normal diet, daily insulin dose decreased from…
- Diabetes mellitus刘某
After 3 administrations: no sleep complaints, strength and psycho-emotional state significantly…
- Diabetes mellitus童某平 · 50
After one course of stem cell therapy, serum insulin rose from 6.81 µIU/mL to 8.94 µIU/mL —…
Discuss your case
Share your diagnosis and history — the academic board responds within 24 hours with a preliminary assessment and protocol outline.
Get a consultation